**Review Article**

**KangFuXin Liquid in the Treatment of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis**

Ke Shen Qu,1,2 Yang Li,1 Yue Liang,1 Xiao Jie Hu,1 Xuan Yu Wang,1 Xin Chen,1 and Hua Fa Que1

1Department of Traditional Chinese Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
2Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Correspondence should be addressed to Hua Fa Que; huafaque@126.com

Received 28 May 2019; Revised 31 August 2019; Accepted 12 September 2019; Published 30 December 2019

Academic Editor: Arthur De Sá Ferreira

Copyright © 2019 Ke Shen Qu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Diabetic foot ulcer (DFU) is one of the most common complications of diabetes mellitus, with the wound not healing as expected and healing slowly. Poor control can develop into gangrene and even amputation. Currently, the existing treatments are not satisfactory enough. In China, KangFuXin liquid (KFXL) has been clinically used to treat DFU and has shown good clinical efficacy. In order to provide more reference to clinicians and experts, evidence of efficacy for it needs to be further rigorously evaluated.

**Methods.** Eight electronic databases were searched to identify eligible randomized clinical trials (RCTs) published from construction of the library to April 2019. There is no language or data restriction; 11 trials involving 889 participants met the inclusion criteria. The Cochrane Handbook guidelines were used to assess the risk of bias and to evaluate the methodological quality of eligible studies. The methodological quality of included studies was generally low. Dichotomous and continuous data were presented using risk ratios (RRs) and mean differences (MDs), respectively.

**Results.** Compared with the basic treatment, meta-analyses showed that KFXL combined with basic treatment can improve the total effective rate (RR = 1.38; 95% CI = 1.23–1.54; \(P < 0.00001\); fixed effect model: \(I^2 = 32\%\)) and cure rate (RR = 1.67; 95% CI = 1.17–2.38; \(P = 0.005\); random effect model: \(I^2 = 65\%\)), and shorten the healing time (MD = −5.73; 95% CI = −6.95 to −4.52; \(P < 0.00001\); random effect model). Moreover, under the same basic treatment, KFXL had a better effect than external use of pharmaceutical medications (RR = 1.95; 95% CI = 1.30–2.93; \(P = 0.001\)), but the cure rate was not significantly different. Also, KFXL had nothing to do with adverse reactions.

**Conclusion.** The evidence confirms that KFXL is an effective treatment for DFU. However, further large-scale, rigorously designed trials and high-quality studies are needed to confirm the role of KFXL in the treatment of DFU.

1. **Introduction**

Diabetic foot ulcer (DFU), which is usually associated with peripheral neuropathy, limb circulatory disturbance, and infection, is one of the most common complications of diabetes mellitus. The incidence rate of DFU is about 4–10% and continuing to grow [1]. Compared with healthy individuals, the repair of wounds in patients with DFU is slow. The wound cannot heal as expected and develop into gangrene or even amputation. Therefore, compared with nondiabetic patients, patients with DFU have higher amputation rates and mortality [2], and amputation rates account for 70% of nontraumatic amputations worldwide [3], which brings severe economic stress and mental burden to them [4]. According to the “Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene,” the recommended treatment for DFU mainly includes glucose-level control, anti-infection, surgical debridement, and external use of growth factor [1]. However, the effectiveness of the recommended treatment is not satisfying enough. Even with a comprehensive treatment regimen, the cure rate of DFU at 12 to 20 weeks is as low as 24% to 30% [5, 6], and even if the ulcer heals after treatment, the risk of recurrence is as high as ten times [7].
Given the above, more effective treatment options should be considered. KFXL, a pure Chinese herbal medicine extracted from the *Periplaneta americana*, has been widely used to treat various ulcerative diseases, especially skin ulcers. The *Periplaneta americana* was first recorded in the Han Dynasty ancient books named “Shen Nong’s Herbal Classic,” which has the effect of breaking through the phlegm, resolving to accumulate, reducing swelling, detoxify, and activating blood to resolve stasis [8]. It has been used for thousands of years to treat snake bites, skin ulcers, and burns. Pharmacological research shows KFXL can enhance immunity, reduce inflammation, promote epidermal cell growth, granulation tissue proliferation to repair the damage, and accelerating the repair and regeneration of damaged tissue to promote wound healing [9–15]. In China, this pure traditional Chinese medicine extract has been widely used in the clinical treatment of DFU. The clinical efficacy of KFXL has been reported in some clinical studies [16].

However, there is currently no systematic review to fully evaluate the clinical evidence for the treatment of DFU with KFXL. Therefore, we evaluated the effectiveness of KFXL in the treatment of DFU through systematic reviews and meta-analysis.

## 2. Materials and Methods

Before initiating the review process, the review protocol was registered in the PROSPERO database (CRD42019131516). We performed this study according to the Cochrane Handbook for Systematic Reviews of Interventions and followed the instruction of Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

### 2.1. Data Search Strategies

Two reviewers used the search terms “KangFuXin solution,” “KangFuXin liquid,” “diabetic foot,” “diabetic foot ulcer” to systematically search for relevant randomized clinical trials (RCTs) in PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), WanFang Database, Chinese Biomedical Literature Database (CBM), Chinese Scientific Journals Database (VIP), and Google Scholar. The search time limit was between the construction of the library to April of 2019. There was no restriction on the language and the type of publication, including proceedings, postgraduate theses, and papers with abstracts only.

### 2.2. Inclusion Criteria

#### 2.2.1. Types of Studies

We selected all the RCTs for meta-analysis. Quasi-RCTs, non-RCTs, and randomized trials with false randomization methods were excluded.

#### 2.2.2. Participants

Those diagnosed with DFU by the World Health Organization (WHO), International Federation of Vascular Diseases (IUA), Chinese Medical Association (CMA), or other authoritative diagnostic criteria, regardless of the age, gender, nationality, and ethnicity.

#### 2.2.3. Intervention

The experimental group used KFXL combined with basic treatment (basic internal medical treatment and conventional debridement). The administration method of KFXL was not limited (wet application, spraying, or rinsing), and the dressing is not limited (sterile dry gauze or vaseline gauze). Basic internal medical treatments included blood glucose control and anti-infective, and the administration methods are oral, intravenous infusion, and subcutaneous administration; Conventional debridement included saline or hydrogen peroxide to flush wound secretions, iodophor disinfection, and surgical debridement to remove necrotic tissue.

#### 2.2.4. Control Group

The control group was patient with DFU who was not treated with KFXL only received basic treatment.

#### 2.2.5. Outcome Measures

The primary outcome was the total effective rate during treatment, defined by changes in the size of the wound ulcer. The calculation formula is as follows: total effective rate = cure rate + effective rate. We also evaluated the cure rate and cure time during treatment, defined by the complete healing of the ulcer, as well as adverse events.

The study will be excluded if any of the following is true: 1. The original data of the literature was incomplete or erroneous, the effective rate was unclear, and the data cannot be extracted, resulting in the inability to assess the primary or secondary outcome 2. Animal experiments, case reports, literature reviews, and systematic reviews; 3. The experimental group had oral or external interventions for other traditional Chinese medicine preparations other than KFXL.

### 2.3. Data Extraction

Two authors (Ke Shen Qu, Xiao Jie Hu) extracted basic information independently according to the mentioned inclusion criteria. Further discussions by the third author (Hua Fa Que) helped resolve the disagreement. The data extracted from the enrolled literature included the following: first author’s name, publication time, literature source, diagnostic criteria, a sample size of the experimental group and control group, intervention measures, intervention time, frequency of medication, outcome index, adverse events, and manufacturer of KFXL.

### 2.4. Risk of Bias Assessment

Each of the included RCTs needs to be assessed for risk of bias, which was done independently by the two author (Xin Chen, Xuan Yu Wang) using the Cochrane Risk of bias tool [17], and the disputed part resolves the disagreement through negotiation or a third author (Hua Fa Que).

### 2.5. Statistical Analysis

We performed this meta-analysis using Revman 5.3 software (Cochrane Collaboration) [18]
Evidence-Based Complementary and Alternative Medicine

3.4.1. Total effective Rate of KFXL Combined with Basic
treatment alone. Using the fixed effect model, analysis showed a significant difference in the total effective rate of the KFXL combined with basic treatment compared with the basic treatment alone (RR = 1.38; 95% CI, 1.23–1.54; P < 0.00001; \(I^2 = 32\%\)) (see Figure 3).

3.4.2. Total effective Rate of KFXL versus External Use of Pharmaceutical Medications Based on Same Basic Treatment. The 3 RCTs [25–27] contained 130 patients. Under same basic treatment, the total effective rate between KFXL and external use of pharmaceutical medications was compared. Using the fixed effect model analysis results, the total effective rate of KFXL showed a significant difference compared with the external use of pharmaceutical medications (RR = 1.95; 95% CI, 1.30–2.93; P = 0.001; \(I^2 = 15\%\)) (see Figure 4).

Based on different use of pharmaceutical medications, the control group can be divided into two different subgroups: external use insulin alone and external use insulin combined with antibiotic. Two trials [25, 26] compared the KFXL and external use of insulin, and the results showed that there was a significant difference in KFXL compared with external use of insulin (RR = 2.05; 95% CI, 1.3–3.23; P = 0.002); 1 trial [27] compared the KFXL and external use of insulin combined with antibiotics. However, the results showed that there was no difference in the total effective rate (RR = 1.50; 95% CI, 0.60–3.74; P = 0.38).

3.4.3. Total Effective Rate of KFXL Combined with Insulin versus External Use of Insulin Based on Same Basic Treatment. 1 trial [28] compared external use of KFXL combined with insulin and external use of insulin based on same basic treatment. The results showed that there was a significant difference between external use of KFXL combined with insulin (RR = 1.30; 95% CI, 1.01–1.68; P = 0.04).

3.5. Secondary Outcomes

3.5.1. Cure Rate

(1) Cure rate of KFXL combined with basic treatment versus basic treatment: 5 trials [20, 21, 23, 29, 30] containing 502 cases was reported the cure rate. The experimental group was treated with basic treatment combined with KFXL, and the control group was treated with basic treatment. Using the random effect model, the results of the analysis showed that there was a significant difference between basic treatment combined with KFXL compared with basic treatment alone (RR = 1.67; 95% CI, 1.17–2.38; P = 0.005; \(I^2 = 65\%\)) (see Figure 5).

(2) Cure rate of KFXL combined with insulin versus external use of insulin based on same basic treatment: 1 trial [25] compared external use of KFXL and insulin under same basic treatment. The results showed that there was no significant difference between KFXL and external use of insulin (RR = 2.25; 95% CI, 0.51–9.87; P = 0.28).
English databases (n = 3):
EMBASE, PubMed, Cochrane,
Google Scholar

Chinese databases (n = 322):
CNKI, CQVIP, WanFang, SinoMed

Number of articles identified through related articles and citations (n = 1)

Number of duplicate articles removed (English databases n = 1; Chinese databases n = 178)

Number of articles screened (n = 147)

Number of full-text articles assessed for eligibility (n = 64)

Studies excluded, with reasons:
Non-RCT (n = 1)
Mixed interventions (n = 34)
Control group is KFXY (n = 11)
Oral or topical other TCM (n = 6)
No prescribed duration of treatment (n = 1)

Final number of RCTs included in meta-analysis (n = 11)

Figure 1: Summary of the literature identification and selection process.

Table 1: Characteristics of 11 included trials.

| Study             | Intervention | Frequency | Duration of treatment (weeks) | Pharmacological treatment                                                                 | Main outcomes                        | Manufacturer |
|-------------------|--------------|-----------|------------------------------|-----------------------------------------------------------------------------------------|--------------------------------------|--------------|
| Ma and Ji [21]    | KFXL         | 1         | 4                            | Hypoglycemic, antibiotics if necessary                                                   | Total effective rate                 | Good doctor  |
|                   |              |           |                              |                                                                                         | Bacterial count                      |              |
|                   |              |           |                              |                                                                                         | Cure rate                            |              |
|                   |              |           |                              |                                                                                         | Cure time                            |              |
| Huang et al. [29] | KFXL         | 1         | NR                           | Insulin, antibiotics if necessary, nutritional support                                    |                                      | SINOWAY      |
| Wang and Qu [23]  | KFXL         | 1         | 3                            | Insulin, antibiotics, improve blood circulation, nutritional support                     | Total effective rate                 |              |
|                   |              |           |                              |                                                                                         |                                      |              |
|                   |              |           |                              |                                                                                         |                                      |              |
|                   |              |           |                              |                                                                                         |                                      |              |
| Huang and Lin [20] | KFXL         | 1-2       | 4                            | Insulin, antibiotics                                                                   | Cure rate                            |              |
|                   |              |           |                              |                                                                                         |                                      |              |
|                   |              |           |                              |                                                                                         |                                      |              |
| Gong et al. [30]  | KFXL         | 1-2       | 6                            | Insulin, antibiotics if necessary                                                       | Total effective rate                 | Good doctor  |
|                   |              |           |                              |                                                                                         | Cure time                            |              |
|                   |              |           |                              |                                                                                         | Shrinkage rate                       |              |
|                   |              |           |                              |                                                                                         | Nerve conduction velocity            |              |
| Qi et al. [22]    | KFXL         | 1         | 2                            | Vasodilator                                                                         |                                      | Good doctor  |
| Feng and Zhao [28]| KFXL plus insulin | 1         | 3                            | Insulin, improve blood circulation, antibiotics if necessary, nutritional support       | Total effective rate                 | SINOWAY      |
|                   |              |           |                              |                                                                                         | Cure time                            |              |
|                   |              |           |                              |                                                                                         | Total effective rate                 |              |
|                   |              |           |                              |                                                                                         |                                      |              |
|                   |              |           |                              |                                                                                         |                                      |              |
| Shi et al. [25]   | KFXL         | 1         | 2                            | Insulin                                                                   | Total effective rate                 | Good doctor  |
|                   |              |           |                              |                                                                                         | Cure time                            |              |
|                   |              |           |                              |                                                                                         | Total effective rate                 |              |
| Sun and Gong [26] | KFXL         | 4         | 4                            | Insulin, improve blood circulation, antibiotics if necessary                            | Oxygen partial pressure              | NR           |
|                   |              |           |                              |                                                                                         | blood flow velocity                  |              |
|                   |              |           |                              |                                                                                         |                                      |              |
|                   |              |           |                              |                                                                                         |                                      |              |
| Yu et al. [27]    | KFXL         | 1         | 4                            | Insulin, antibiotics if necessary, nutritional support, vasodilator                   | Total effective rate                 | Good doctor  |
|                   |              |           |                              |                                                                                         | Cure time                            |              |
|                   |              |           |                              |                                                                                         | Total effective rate                 |              |
|                   |              |           |                              |                                                                                         | Cure time                            |              |
| Zou and Liu [24]  | KFXL         | 1         | 4                            | Insulin, antibiotics if necessary                                                       | Anxiety and depression score         | KELUN        |

NR, no report.
| Study                  | Sample | Age          | Duration of treatment (years) | Diagnostic criteria | Wagner | Baseline data comparable | Incomplete outcome data | Selective reporting | ADs                  |
|-----------------------|--------|--------------|------------------------------|---------------------|--------|--------------------------|------------------------|---------------------|---------------------|
| Ma [21]               | 21     | 21           | 52.4 ± 4.2                  | WHO                 | Yes    | Yes                      | No                     | No                  | NR                  |
| Huang [29]            | 50     | 50           | NR                          | NR                  | Yes    | Yes                      | No                     | No                  | NR                  |
| Wang and Qu [23]      | 50     | 50 NR        | 57.9 ± 8.9                  | NR                  | No     | Yes                      | No                     | No                  | NR                  |
| Huang [15]            | 67     | 67 NR        | 54 ± 56                     | WHO1995             | Yes    | Yes                      | No                     | No                  | NR                  |
| Gong [30]             | 60     | 60 69.8      | NR                          | CMA1995             | No     | Yes                      | No                     | No                  | NR                  |
| Qi [22]               | 51     | 50 65.1 ± 5.7| 7.9 ± 3.1                  | IUA2013             | No     | Yes                      | No                     | No                  | NR                  |
| Feng and Zhao [28]    | 28     | 28 34–70     | 38–69                       | NR                  | Guidelines of type 2 diabetes in China 2007 | No     | Yes                      | No                     | No                  | NR                  |
| Shi [25]              | 24     | 18 59.5 ± 9.8| 66.5 ± 8.1                  | ADA                 | Yes    | Yes                      | No                     | No                  | NR                  |
| Sun and Gong [26]     | 38     | 30 60.2 ± 5.5| 11.4 ± 3.6                  | WHO2007             | Yes    | Yes                      | No                     | No                  | NR                  |
| Yu [27]               | 10     | 10 40–65     | 10.6 ± 4.4                  | WHO1999             | Yes    | Yes                      | No                     | No                  | NR                  |
| Zou and Liu [24]      | 50     | 50 50.40 ± 1.92| 50.14 ± 1.53                  | NR                  | No     | Yes                      | No                     | No                  | NR                  |

E, experimental group; C, control group; ADs, adverse events; NR, no report; ADA, American Diabetes Association; WHO, World Health Organization; IUA, International Union of Angiology; CMA, Chinese medical association.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other biases

Figure 2: Risk of bias graph.

| Study or subgroup                        | Experimental Events | Control Events | Weight (%) | Risk ratio  | Risk ratio  |
|------------------------------------------|---------------------|----------------|------------|-------------|-------------|
|                                          | Events              | Total          |            | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| 1.1.1. Kangfuxin Liquid plus Basic Treatment versus Basic Treatment |                     |                |            |             |             |
| Ma 2016                                  | 10                  | 21             | 1.4        | 5.00 [1.24, 20.12] |             |
| Wang 2011                                | 44                  | 50             | 33         | 21.6        | 1.49 [1.17, 1.90] |
| Qi 2018                                  | 39                  | 51             | 33         | 23.1        | 1.16 [0.90, 1.49] |
| Zou 2019                                 | 44                  | 50             | 34         | 23.5        | 1.29 [1.04, 1.61] |
| Huang 2009                               | 60                  | 67             | 44         | 30.5        | 1.36 [1.13, 1.65] |
| Subtotal (95% CI)                        | 239                 | 244            | 100.0      | 1.38 [1.23, 1.54] |             |
| Total events                             | 197                 | 146            |            |             |             |
| Heterogeneity: chi² = 5.90, df = 4 (P = 0.21); I² = 32% |             |                |            |             |             |
| Test for overall effect: Z = 5.54 (P < 0.00001) |             |                |            |             |             |
| Total (95% CI)                           | 239                 | 244            | 100.0      | 1.38 [1.23, 1.54] |             |
| Heterogeneity: chi² = 5.90, df = 4 (P = 0.21); I² = 32% |             |                |            |             |             |
| Test for overall effect: Z = 5.54 (P < 0.00001) |             |                |            |             |             |
| Test for subgroup difference: not applicable |             |                |            |             |             |

Figure 3: The total effective rate of KFXL combined with basic treatment versus basic treatment.

| Study or subgroup                        | Experimental Events | Control Events | Weight (%) | Risk ratio  | Risk ratio  |
|------------------------------------------|---------------------|----------------|------------|-------------|-------------|
|                                          | Events              | Total          |            | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| 1.2.1. Kangfuxin Liquid versus External Use of insulin |                     |                |            |             |             |
| Shi 2010                                 | 17                  | 24             | 8          | 43.6        | 1.59 [0.90, 2.84] |
| Sun 2014                                 | 23                  | 38             | 7          | 37.3        | 2.59 [1.29, 5.21] |
| Subtotal (95% CI)                        | 62                  | 48             | 80.9       | 2.05 [1.31, 3.23] |             |
| Total events                             | 40                  | 15             |            |             |             |
| Heterogeneity: chi² = 1.17, df = 1 (P = 0.28); I² = 15% |             |                |            |             |             |
| Test for overall effect: Z = 3.11 (P = 0.002) |             |                |            |             |             |
| 1.2.2. Kangfuxin Liquid versus External Use of insulin plus Antibiotic |                     |                |            |             |             |
| Yu 2008                                  | 6                   | 16             | 10         | 19.1        | 1.50 [0.60, 3.74] |
| Subtotal (95% CI)                        | 10                  | 10             | 19.1       | 1.50 [0.60, 3.74] |             |
| Total events                             | 6                   | 4              |            |             |             |
| Heterogeneity: not applicable             |                     |                |            |             |             |
| Test for overall effect: Z = 0.87 (P = 0.38) |             |                |            |             |             |
| Total (95% CI)                           | 72                  | 58             | 100.0      | 1.95 [1.30, 2.93] |             |
| Total events                             | 46                  | 19             |            |             |             |
| Heterogeneity: chi² = 1.43, df = 2 (P = 0.49); I² = 0% |             |                |            |             |             |
| Test for overall effect: Z = 3.22 (P = 0.001) |             |                |            |             |             |
| Test for subgroup difference: chi² = 0.37, df = 1 (P = 0.54); I² = 0% |             |                |            |             |             |

Figure 4: The total effective rate KFXL versus external use of pharmaceutical medications based on same basic treatment.
3.5.2. Cure Time

(1) Cure time of KFXL combined with basic treatment versus basic treatment: 3 trials [22, 24, 29] containing 301 cases reported the rate of cure time. The experimental group was treated with KFXL under basic treatment, and the control group was treated with basic treatment alone. Using the random effect model, the results showed that the cure time of KFXL combined with basic treatment was significantly lower than basic treatment alone (MD = −5.73; 95% CI, −6.95 to −4.52; P < 0.00001) (see Figure 6).

(2) Cure time of KFXL and external use of pharmaceutical medications based on same basic treatment: 1 trial [27] compared the KFXL and insulin combined with antibiotic based on basic treatment. The results showed that the two therapies had differences in healing time (MD = −4.70; 95% CI, −8.30 to −1.10; P = 0.01).

3.6. Adverse Events. Only 1 trial [22] reported adverse events during treatment in 11 trials included, describing the incidence of adverse events in the experimental and control groups. Adverse events mainly manifested as headache, dizziness, palpitations, and dysfunction of liver and kidney, caused by basic internal medical treatment—oral cilostazol—the contrast was not statistically significant. The remaining trials did not describe the occurrence of adverse reactions during the use of KFXL.

4. Discussion

4.1. Summary of Outcomes. We finally included 11 RCTs involving 889 patients after extraction. They used an ethanol extract of Periplaneta americana, collectively known as KFXL, to intervene in DFU patients and judge their clinical effects, even though they came from different manufacturers but had the same ingredients. We did the meta-analysis based on that.

Compared with the basic treatment, KFXL combined with basic treatment can improve the total effective rate, healing rate, and shorten the healing time. Through subgroup analysis results, under the same basic treatment, KFXL was compared with the external use of insulin, the former has better efficiency than the latter. Other than this, KFXL compared with external use of insulin combined with antibiotics can promote wound cure time but has no effect on total effective rate. The above results may represent that the main mechanism of KFXL in the treatment of DFU may be mainly based on repair and promotion of healing. 1 trial [26] also reported the effects of KFXL on transcutaneous oxygen pressure and flowing velocity of dorsal foot blood. After the treatment, the transcutaneous oxygen pressure and the flowing velocity of dorsal foot blood were significantly increased. This suggests that the KFXL may be able to increase the local blood supply, which coincides with the theory of Chinese medicine that can activate blood to resolve stasis.

KFXL is considered to be unrelated to adverse reactions. Adverse effects reported in these trials included headache, dizziness, palpitations, and liver and kidney dysfunction. But statistical analysis was not associated with KFXL and was more likely to be caused by internal medical treatment. Therefore, KFXL is considered to be a better choice for clinical treatment of DFU.

4.2. Advantages and Limitations. In the 11 studies we included, no sample loss was reported, and all the outcomes were reported. All the subjects were Chinese, the gender ratio was balanced, and the age was mainly middle aged and elderly. Although this study clarifies the possibility of KFXL as a viable treatment option for DFU, there are still some limitations to this meta-analysis. Within all trials, only 1 trial [22] reported the blinded information to participants and researchers, but the rest trials did not mention the use of blinding. All of the trials are mentioned for grouping using random methods but did not describe specific methods. Therefore, potential performance bias and detection biases
were caused by insufficient randomization and lack of blinding. Furthermore, this systematic review and meta-analysis only included 11 trials, and the sample size was small. In addition, there were 6 trials [20, 21, 25–27, 29] that conducted Wagner classification, with the proportions from grade I to grade V being 48%, 36%, 11.3%, 4%, and 0.7% respectively. Moreover, the duration of treatment and dose of the KFXL are not consistent. Therefore, we only recommend that the intervention of KFXL for patients with grade I-II mild to moderate DFU may achieve better results and promote repair in the early stage of ulcer formation to avoid the deterioration of the condition caused by difficult healing of the long-term wound. Only 1 trial [22] reported adverse events, indicating that the safety assessment of KFXL was inadequate, so more research on safety and tolerability is still needed. Last but not least, the clinical study on the use of KFXL for the treatment of DFU lacks a detailed and meticulous design. In addition, the quality of the methodology of this research included in this review was generally poor, indicating that there may be high risk of bias.

4.3. Possibility and Rationality of KFXL for the Treatment of DFU. DFU are characterized by slow wound healing. KFXL is rich in active substances such as sex pheromones, proteins, amino acids, affinity peptides, alkaloids, adipokinin hormones, and polysaccharides, which can reduce inflammatory factor, such as IL-6, IL-8, TNF-a, and c-reactive protein, increase CD8+ T-cell activity and SOD content, increase EGF and VEGF in wound tissue, and TGF-β and bFGF levels [31–36]. Recent studies have shown that the mechanism of wound healing from the *Periplaneta americana* extract may be through the regulation of JAK/STAT3, PI3K/AKT, nuclear factor kappa B canonical pathway, and extracellular signal-regulated kinases signaling to affect cell proliferation, fibrogenesis, re-epithelialization, and remodeling [13, 14, 37]. At the same time, the compound periplanosides A-C can stimulate the production of human epidermal fibroblast collagen at a certain concentration [38]. Overall, KFXL, basically an alcohol extract of *Periplaneta americana*, assists in resisting inflammation, diminishing swelling, accelerating the repair of tissue lesions, and enhancing immunity [39].

Complementary and alternative medicine (CAM) is the crystallization of the experience of the Chinese people accumulating in the struggle against diseases. Practitioners of TCM believe that the pathogenesis of DFU is mainly “Qi deficiency and blood stasis.” In the context of TCM, “Qi” can be understood as the general term for the substances, energy, and information that constitute the human body and maintain the life activities of the human body [40]. “Qi deficiency and blood stasis” is a pathological condition. “Qi” can promote the operation of blood. When “Qi” is weak, it is unable to push blood and cause blood stasis. Therefore, whether it is from the perspective of traditional Chinese medicine or modern medicine, KFXL has rationality and possibility in treating DFU.

5. Conclusions

Our systematic review and meta-analysis revealed that KFXL could increase the clinical efficacy of basic treatment. Therefore, we recommend that KFXL is suitable for patients with mild to moderate DFU. This article provides new ideas and new methods for better treatment of DFU in the clinic. In the future, more clinical studies should be designed to confirm the effectiveness and safety of KFXL. It can also be combined with other modern treatments for research. However, the overall methodological and reporting quality of the included trials was limited, and more dedicated design and high-quality studies are needed to confirm the role of KFXL in the treatment of DFU. Therefore, more high-quality large-sample size RCTs are required to confirm and explain it.

### Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| CI           | Confidence interval |
| RCT          | Randomized controlled trials |
| RR           | Risk ratios |
| DFU          | Diabetic foot ulcer |
| KFXL         | KangFuXin liquid |
| E            | Experimental group |
| C            | Control group |
| Ads          | Adverse events |
| NR           | No report |
Ethical Approval

This study was based on previously published studies; therefore, ethical approval and patient consent are not relevant.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

KQ, YL, YL, XH, XW, XC, and HQ had full access to all the study data and take responsibility for its integrity and the accuracy of the analysis. KQ, YL, and HQ were responsible for the study concept and design. KQ and YL were responsible for data acquisition, and XH and KQ were responsible for data extraction. The assessment of bias risk was performed by XC and XW; data analysis and interpretation were performed by YL and YL. The paper was drafted by KQ, while XH and HQ provided critical review of the paper for important intellectual content. KQ performed statistical analyses and HQ supervised the study. KQ, YL, YL, XH, XW, XC, and HQ contributed to the revision of the manuscript. All authors have read and approved the final manuscript.

Acknowledgments

None. This project was supported by NSFC of China (no. 81774317).

Supplementary Materials

The supplementary materials that I have included in the manuscript are PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and cover letter. PRISMA is an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses. (Supplementary Materials)

References

[1] International Diabetes Federation, *IDF Diabetes Atlas*, International Diabetes Federation, Brussels, Belgium, 8th edition, 2017.
[2] M. M. Iversen, G. S. Tell, T. Risse et al., “History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the nord-trondelag Health study, Norway,” *Diabetes Care*, vol. 32, no. 12, pp. 2193–2199, 2009.
[3] International Diabetes Federation, *IDF Diabetes Atlas*, International Diabetes Federation, Brussels, Belgium, 7th edition, 2015.
[4] S. R. Nussbaum, M. J. Carter, C. E. Fife et al., “An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds,” *Value in Health*, vol. 21, no. 1, pp. 27–32, 2018.
[5] P. R. Cavanagh and S. A. Bus, “Off-loading the diabetic foot for ulcer prevention and healing,” *Journal of Vascular Surgery*, vol. 52, no. 3, pp. 375–435, 2010.
[6] P. R. Cavanagh, B. A. Lipsky, A. W. Bradbury, and G. Botek, “Treatment for diabetic foot ulcers,” *The Lancet*, vol. 366, no. 9498, pp. 1725–1735, 2005.
[7] K. Y. Woo, M. Botros, J. Kuhnke, R. Evans, and A. Alavi, “Best practices for the management of foot ulcers in people with diabetes,” *Advances in Skin & Wound Care*, vol. 26, no. 11, pp. 512–524, 2013.
[8] Q. Dynasty and S. X. Huang, *Shen Nong’s Herbal Classic*, Publishing House of Chinese Medical Ancient Books, China, 1982.
[9] Y. Zhao, A. Yang, P. Tu et al., “Anti-tumor effects of the American cockroach, *Periplaneta americana*,” *Chin Med*, vol. 12, no. 1, p. 26, 2017.
[10] L. Y. Jiang, X. Liu, C. L. Xia et al., “Research advance on chemical constituents and anti-tumor effects of *periplaneta americana*,” *Medicinal Plant*, vol. 3, no. 11, pp. 95–97, 2012.
[11] Y. C. Wang, X. D. Jian, Z. C. Zhang, Q. Ning, and B. Zhao, “The experimental study of therapeutical effects of KANG-FUXINYE on upper gastrointestinal injury induced by paraquat in rats,” *Chinese Journal of Industrial Hygiene and Occupational Diseases*, vol. 30, no. 3, pp. 220–222, 2012.
[12] P.-W. Ren, W.-J. Yang, D.-D. Wang et al., “Kangfuxin enema combined with mesalalmine for ulcerative colitis: a systematic review and grade Approach,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2017, Article ID 6019530, 15 pages, 2017.
[13] Q. Song, Y. Xie, Q. Gou, X. Guo, Q. Yao, and X. Gou, “JAK/STAT3 and Smad3 activities are required for the wound healing properties of *Periplaneta americana* extracts,” *International Journal of Molecular Medicine*, vol. 40, no. 2, pp. 465–473, 2017.
[14] Y. Shen, J. Sun, C. Niu et al., “Mechanistic evaluation of gastroprotective effects of Kangfuxin on ethanol-induced gastric ulcer in mice,” *Chemico-Biological Interactions*, vol. 273, pp. 115–124, 2017.
[15] G. Huang, “Benefiting Qi for nourishing blood prescription combined with, Kangfuxin liquid in the treatment of perianal Sjogren’s syndrome 1 cases,” *Guangming Journal of Chinese Medicine*, vol. 18, p. 18, 2017.
[16] S. Duan, L. Tang, Y. Liu, W. Chen, and Y. Jiang, “Effect of traditional Chinese medicine foot bath on 0 level diabetic foot: meta-analysis,” *Chinese Nursing Management*, vol. 16, pp. 159–163, 2016.
[17] J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” *BMJ*, vol. 343, no. oct18 2, p. d5928, 2011.
[18] Nordic Cochrane Centre, *Review Manager (RevMan) [Computer Program]. Version 5.3.*, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark, 2014.
[19] J. P. T. Higgins and S. Green, *Cochrane Handbook for Systematic Reviews of Interventions*, The Cochrane Collaboration, London, UK, 2011.
[20] W. F. Huang and F. W. Lin, “Observation on the effect of Kangfuxin Liquid in treating diabetic foot,” *Chinese Village Medicine*, vol. 17, no. 2, p. 50, 2010.
[21] Y. L. Ma and Q. H. Ji, “Clinical observation of debride and dressing combined with Kangfuxin liquid on diabetic foot ulcer,” *Shaanxi Medical Journal*, vol. 45, no. 5, p. 636, 2016.
[22] J. Z. Qi, L. E. Huo, X. M. Wang et al., "Therapeutic effect of Kangfuxin Liquid combined with cilostazol on diabetic foot," *Modern Medicine and Clinical*, vol. 33, no. 10, pp. 136–139, 2018.

[23] Y. Wang and L. J. Qu, "Effect of Kangfuxin liquid on diabetic foot infection," *LiaoNing Medical Journal*, vol. 25, no. 1, p. 40, 2011.

[24] H. L. Zou and A. Y. Liu, "Observation on the effect of Kangfuxin Liquid combined with dressing for diabetic foot," *Chinese and Foreign Medical Research*, vol. 17, no. 4, pp. 141–142, 2019.

[25] K. L. Shi, "Clinical observation and nursing experience of 24 cases of diabetic foot treated with Kangfuxin liquid wet compress," *Chinese Journal of External Therapy*, vol. 19, no. 5, pp. 26–27, 2010.

[26] F. F. Sun and W. F. Gong, "Treatment of 38 cases of ischemic diabetic foot with Kangfuxin liquid gauze wet compress," *Chinese Practical Medicine*, vol. 9, no. 5, pp. 16–17, 2014.

[27] Q. Yu, J. D. Liu, and Z. Y. Long, "Clinical observation of Kangfuxin Liquid treatment of diabetic foot ulcer," *Clinical Gather*, vol. 23, no. 19, p. 1412, 2008.

[28] Q. Feng and J. Zhao, "Therapeutic effect of Kangfuxin Liquid combined with insulin on diabetic foot," *Journal of Clinical Rational Drug Use*, vol. 26, pp. 52–53, 2015.

[29] X. Y. Huang, "Therapeutic effect of Kangfuxin Liquid combined with dressing on diabetic foot," *Chinese Medicine Guide*, vol. 35, p. 265, 2014.

[30] P. Gong, "Treating 120 cases of diabetic foot with Kangfuxin liquid," *Chinese Journal of External Therapy*, vol. 15, no. 4, pp. 26–27, 2006.

[31] W. Jiang, S. Luo, Y. Wang, L. Wang, X. Zhang, and W. C. Ye, "Constituents from *Periplaneta Americana*," *Chemical Journal of Jinan University*, vol. 36, pp. 294–301, 2015.

[32] P. A. Ayayee, T. Larsen, and Z. Sabree, "Symbiotic essential amino acids provisioning in the American cockroach, *Periplaneta americana* (Linnaeus) under various dietary conditions," *PeerJ*, vol. 4, Article ID e2046, 2016.

[33] J. N. Zeng, X. Liu, M. W. Wu et al., "Effect of *Periplaneta americana* extract on VEGF expression in refractory wounds of rats," *Chinese National Folk Medicine*, vol. 25, no. 19, pp. 64–66, 2016.

[34] T. T. Liu, X. S. Huang, J. Chen et al., "Effect of Kangfuxin liquid on the repair of gastric mucosa in rat model of acetic acid stinky gastric ulcer," *Lishizhen Medicine and Materia Medica Research*, vol. 23, no. 12, pp. 3028–3030, 2012.

[35] Y. H. Guo, H. Yuan, X. Y. Zhang et al., "Effects of *Periplaneta americana* extract on expression of EGF and IGF-1 in rats with ulcerative colitis," *Journal of Weifang Medical College*, vol. 37, no. 2, pp. 125–127, 2015.

[36] S. Q. Yang, Q. Xiong, J. B. Zhou et al., "Effect of aqueous extract of *American cockroach* on scald model in mice," *Chinese Journal of Experimental Formulaology*, vol. 22, no. 22, pp. 145–149, 2016.

[37] J. J. Zhu, S. Yao, X. Guo et al., "Bioactivity Guided screening of wound-healing active constituents from *American cockroach* (*Periplaneta Americana*)," *Molecules*, vol. 23, p. 101, 2018.

[38] Y. X. Yang, Q. Luo, B. Hou et al., "Periplanosides A–C: new insect-derived dihydroisocoumarin glucosides from *Periplaneta americana* stimulating collagen production in human dermal fibroblasts," *Journal of Asian Natural Products Research*, vol. 17, no. 10, pp. 988–995, 2015.

[39] F. Geng and G. Chen, "*Periplaneta americana* extract or *Periplaneta americana* medicinal powder as well as preparation method thereof and application in preparation for..."